Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 27;149(7):1133–1139. doi: 10.1093/jn/nxz029

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © American Society for Nutrition 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Efficacy outcomes for patients with metastatic colorectal cancer receiving either FOLFOX or CUFOX. Kaplan–Meier plots show (A, B) PFS and OS in per-protocol populations (n = 9 for FOLFOX, n = 15 for CUFOX) and (C, D) PFS and OS in those patients that did not go on to receive surgical intervention (n = 7 for FOLFOX, n = 16 for CUFOX). Survival time is shown in days. OS and PFS were compared between treatment arms using log-rank tests. CUFOX, folinic acid/5-fluorouracil/oxaliplatin + 2 g oral curcumin/d; FOLFOX, folinic acid/5-fluorouracil/oxaliplatin; OS, overall survival; PFS, progression-free survival.